![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support Navega's NT-Z001, which is being evaluated in the IND enabling stage for the treatment of chronic pain associated with rare diseases such as small fiber neuropathy and primary erythromelalgia.
Lead Product(s): NT-Z001
Therapeutic Area: Neurology Product Name: NT-Z001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Charles River Laboratories, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2024